Genzyme taps C&W for pre-launch drug comms

CAMBRIDGE, MA: Genzyme hired Cohn & Wolfe to provide global pre-launch communications for alemtuzumab, a multiple sclerosis drug that received fast-track status from the Food and Drug Administration in June.

CAMBRIDGE, MA: Genzyme hired Cohn & Wolfe to provide global pre-launch communications for alemtuzumab, a multiple sclerosis drug that received fast-track status from the Food and Drug Administration in June.

The drug is already approved to treat a form of leukemia. John Lacey, associate director of corporate communications at Genzyme, confirmed Cohn & Wolfe had won the account.

Mike Kan, global healthcare practice leader, and Lisa Talbot, EVP and co-director of the New York healthcare practice, are leading the account for Cohn & Wolfe, said Eric Litchfield, VP of communications for the firm.

Alemtuzumab is currently enrolled in two phase three clinical trials and the company said data is expected by 2011.

In recent weeks, media outlets have speculated that Sanofi-Aventis is looking at Cambridge, MA-based Genzyme as an acquisition target.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in